When was Cellply founded?

Cellply was founded in 2013 and raised its 1st funding round 1 year after it was founded.

Where is Cellply located?

Cellply is headquartered in Bologna, Italy.

How many employees does Cellply have?

As of Jun 30, 2026, the latest employee count at Cellply is 27.

Is Cellply a funded company?

Cellply is a funded company, having raised a total of $16.4M across 10 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on Mar 20, 2014.

When was the latest funding round of Cellply?

Cellply's latest funding was a $***** Series B round on May 11, 2026, with participation from 2 investors.

Where does Cellply rank among its competitors?

Cellply ranks 2nd amongst 115 active competitors, of which 30 are funded. It stands 5th in terms of total funding among its competitors. The most recent competitor to raise funding was Cellply, which secured $8.36M in May, 2026.

Who are the top competitors of Cellply?

Cellply's top competitors include Bit.bio, CytoTronics and Kiyatec. Among them, Cellply secured the most recent funding round in May, 2026.

Cellply - 2026 Company Profile, Team, Funding & Competitors

Company Details

Developer of in-vitro diagnostic products for the detection of cancer. The company has developed ONCOSMART is the first In-Vitro Diagnostic (IVD) system that determines the effectiveness of anticancer drugs for a specific patient, testing live cell response to one or multiple cancer drugs. Additionally, it offers prognostic tests based on the immune profile of hospitalized patients with Coronavirus Disease 19.

Website: www.cellply.com/
Social
Email ID: *****@cellply.com
Phone Number: +39 **********

Key Metrics

Founded Year

2013

Location

Bologna, Italy

Stage

Series B

Total Funding

$16.4M in 10 rounds

Latest Funding Round

Series B, May 11, 2026, $*****

Investors

LIFTT & 16 more

Ranked

2^nd among 115 active competitors

Employee Count

27 as on Jun 30, 2026

Similar Companies

Bit.bio & 155 more

View Cellply's full profile

Cellply has raised a total funding of $16.4M over 10 rounds. Its first funding round was on Mar 20, 2014. Its latest funding round was a Series B round on May 11, 2026 for $*****. 2 investors participated in its latest round. Cellply has 16 institutional investors and 1 angel investor.

Here is the list of recent funding rounds of Cellply:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
May 11, 2026	5336437	Series B	2087734	6385622	3066796	9403897
Sep 29, 2023	2462835	Series A	9214362	8605432	9541410	Schia Ventures
Sep 01, 2022	7881364	Grant (prize money)	3340116	9247042	2978564	Europa

Access funding benchmarks and valuations. Sign up today!

View details of Cellply's funding rounds and investors

The founders of Cellply is Roberto Guerrieri.

Here are the details of Cellply's key team members:

Roberto Guerrieri: Co-Founder of Cellply and founder of 1 other company.
Contact Info: 2 email addresses

View details of Cellply's Founder profiles and Board Members

Cellply's employee count trend

Cellply has 27 employees as of Jun 26. Here is Cellply's employee count trend over the years:

Uncover Cellply's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Cellply include Bit.bio, CytoTronics and Kiyatec. Here is the list of Top 10 competitors of Cellply, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Bit.bio 2016, Cambridge (United Kingdom), Series C	Manufacturer of programmed human cells for research and drug discovery	$266M	M&G, Foresite Capital & 53 others	68/100
2nd	Cellply 2013, Bologna (Italy), Series B	Developer of in-vitro diagnostic products for the detection of cancer	$16.4M	Indaco Venture Partners, European Innovation Council ... & 15 others	60/100
3rd	CytoTronics 2015, Boston (United States), Series A	Developer of cell-based assays for drug discovery	$22.8M	Anzu Partners, BoxOne Ventures & 1 others	56/100
4th	Kiyatec 2005, Pendleton (United States), Series C	Develops 3D phenotypic cell-based assays and diagnostic solutions for prediction of patients’ response to cancer drug treatment	$29.5M	VentureSouth, MBD Biotech & 13 others	55/100
5th	Saguaro 2020, Quebec City (Canada), Seed	Developer of 3D cell culture products for drug discovery	$4.1M	Anges Quebec, AQC Capital & 3 others	49/100
6th	Pelago Bioscience 2013, Solna (Sweden), Seed	Assay services for use in the determination and quantification of drug-target interactions	-	Impilo, Europa & 1 others	48/100
7th	Cytotheryx 2018, Rochester (United States), Series A	Developer of human hepatocytes for research and clinical applications	$60M	Ouroboros Family Founders Fund I, QRS Investments ... & 1 others	47/100
8th	StemBioSys 2010, San Antonio (United States), Series A	Cell culture technology company advancing regenerative medicine and drug discovery	$14.5M	JLABS, Targeted Technology & 3 others	45/100
9th	Nanocrine 2018, Frederick (United States), Seed	Provider of a cell analysis and drug design tool for researchers	$300K	TEDCO, America’s Seed Fund	43/100
10th	Alomone 1989, Jerusalem (Israel), Unfunded	Supplier of ion channel, GPCR and neural signaling tools	-	-	41/100